John B. Cannon, Ph.D Achondroplasia is a form of dwarfism that occurs about once in every 20,000 births. It arises…
QED
SAN FRANCISCO, May 11, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in…
March 27, 2020
QED COVID-19 Update
Dear Chandler Project, We at QED know that this is a challenging time for all families. We hope that you…
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a…
December 20, 2019
QED Achondroplasia Clinical Update
QED Therapeutics, Inc. (“QED”), a subsidiary of BridgeBio Pharma, Inc. (“BridgeBio”) focuses on bringing medicine to people living with conditions…
The Chandler Project 🦋
The Chandler Project provides those affected with achondroplasia, and other forms of dwarfism and skeletal dysplasia, with the latest in pharmaceutical research and surgical advancements. The Chandler Project believes in advocacy, awareness, support, and hope for all.